KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Shares Outstanding (Diluted Average) (2020 - 2025)

Pacific Biosciences Of California (PACB) has 7 years of Shares Outstanding (Diluted Average) data on record, last reported at $300.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 4.02% year-over-year to $300.0 million; the TTM value through Dec 2025 reached $300.0 million, up 4.02%, while the annual FY2025 figure was $300.0 million, 4.02% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $300.0 million in Q4 2025 per PACB's latest filing, roughly flat from $300.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $300.8 million in Q3 2025 and bottomed at $198.5 million in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $251.9 million, with a median of $249.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 29.59% in 2021, then rose 4.02% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $204.1 million in 2021, then increased by 10.0% to $224.6 million in 2022, then grew by 12.95% to $253.6 million in 2023, then grew by 13.7% to $288.4 million in 2024, then grew by 4.02% to $300.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $300.0 million in Q4 2025, $300.8 million in Q3 2025, and $300.2 million in Q2 2025.